Select a Region North America

Access Challenges for Severe Infectious Diseases

Content for this article was provided by EVERSANA’s Asia Pacific team.

The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality rate. These diseases have poor prognoses and high mortality rates. Disease severity and mortality rates have been increased by anti-microbial/antibiotic resistance. Large gaps exist in the pipeline, with only 18% of antibiotic clinical development being innovative. Manufacturers face challenges in addressing the lack of differentiation in their drugs. In addition to clinical unmet needs, different markets offer a variety of access challenges.

Complete the form below to learn more about US, EU5 and APAC access challenges and how these challenges can be reshaped

Author Team
no-image

EVERSANA employs a team of over 6000 professionals across 40+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…